Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting
Open Access
- 25 November 2013
- journal article
- review article
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (4) , 872-884
Abstract
No abstract availableKeywords
This publication has 134 references indexed in Scilit:
- Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantationLiver Transplantation, 2012
- Review and management of drug interactions with boceprevir and telaprevirHepatology, 2012
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1New England Journal of Medicine, 2012
- Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver InjuryGastroenterology, 2011
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Standardization of nomenclature and causality assessment in drug‐induced liver injuryHepatology, 2010
- Causality Assessment in Drug-Induced Liver Injury Using A Structured Expert Opinion Process: Comparison to the Roussel-Uclaf Causality Assessment MethodHepatology, 2010
- Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United StatesGastroenterology, 2008
- Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury†‡Hepatology, 2008